Aequus Provides Additional Disclosure in Connection with Annual General and Special Meeting of Shareholders

Core Points - Aequus Pharmaceuticals Inc. is providing additional information regarding its upcoming annual general and special meeting scheduled for November 21, 2025, at the request of the Ontario Securities Commission [1][2] - The company is clarifying details about a potential share consolidation, stating it will not proceed if certain conditions regarding market price changes or undisclosed material facts are met [3] - The company is also supplementing information related to cease trade orders affecting a director nominee, Marc Lustig, due to non-compliance with insider reporting requirements [5] Company Information - Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutics areas within the Canadian market [6]